MOH — authorised 29 August 2017
- Marketing authorisation holder: REMPEX PHARMS INC
- Status: likely_approved
MOH authorised Vabomere on 29 August 2017
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 29 August 2017.
REMPEX PHARMS INC holds the Israeli marketing authorisation.